Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Strategy Inc. (MSTR) Price & Performance

Charles River Laboratories Intl. IncTrade
Strategy Inc.Trade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Strategy Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $231.21 (market cap $11.14B), while Strategy Inc. trades at $97.63 (market cap $35.38B). The key difference: Strategy Inc. is far larger — about 3.2× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.

CRLMSTR
Market Cap
$11.14B$35.38B
Sector
HealthTechnology
52-Week High
$233.60$455.90
52-Week Low
$145.57$82.31
Enterprise Value
$14.00B$50.42B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Strategy Inc.

MSTR trades at $92.10, down 2.68% on the day, reflecting bearish technical signals and volatile earnings. The stock shows a low P/E of 5.3 and P/B of 0.91, but negative profitability metrics like a net income margin of -2,482.01% highlight financial strain. Recent news indicates scrutiny over Bitcoin-related strategy shifts, with cash flow heavily influenced by financing activities.

Outlook remains cautious due to persistent losses and high debt, though analyst consensus is bullish with a $237.63 price target. Key risks include earnings volatility and reliance on financing; investors should weigh valuation against fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR